about
Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyAntiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.
P2860
Q26782270-B9D0637C-2079-4C25-91C9-C3453D7C17A2Q26801716-C089EB30-3613-40C2-9A33-8D5B2983726BQ30240160-18580E23-ABA0-4468-A401-FDD2859C53FBQ35223221-8BCA900E-39CD-495D-A5E0-DEB2F6518645Q36406996-1825EF35-02AD-4DC4-A556-C2B16A256C9CQ38434473-B3FC8A53-DEF3-403E-9D50-9514D6FB4378Q38649847-1C65BC58-EF6F-4160-868F-4322C4516B5DQ38896683-72D4236C-C267-4AD8-A88F-BF154583E3BAQ40782944-FDDB5876-1262-4D7D-88F4-646724F86568
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Role of CD30 targeting in malignant lymphoma.
@en
type
label
Role of CD30 targeting in malignant lymphoma.
@en
prefLabel
Role of CD30 targeting in malignant lymphoma.
@en
P2860
P1476
Role of CD30 targeting in malignant lymphoma.
@en
P2093
Anas Younes
Anita Kumar
P2860
P2888
P304
P356
10.1007/S11864-014-0275-7
P577
2014-06-01T00:00:00Z
P6179
1015783085